Despite the superiority of the first-generation EGFR-TKIs over chemotherapy in improving patients’ survival, such as gefitinib and erlotinib (5), acquired tolerance still occurs in over half of NSCLC patients (6). This evidence concerns the gene EGFR and non-small cell lung carcinoma.